Compare Agilent Technologies Inc (A) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.36. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Agilent Technologies Inc nearer its low. Which is the better fit depends on your goals.
| A | QQQE | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $122.72 |
52-Week Low | $110.24 | $96.06 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
QQQE trades at $121.96, up 1.61% with strong bullish technical signals from moving averages. The equal-weighted Nasdaq-100 ETF offers diversified exposure to large-cap growth stocks, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential Nasdaq-100 inclusion as a catalyst for equal-weighted strategies.
The ETF's equal-weight approach provides defensive positioning amid tech concentration concerns, with recent outperformance driven by mid-tier growth and biotech exposure. Key risks include market volatility and tech sector sensitivity, while institutional interest grows due to balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
